Año: 2023
Journal Impact Factor (JIF): 4.50
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| CLINICAL NEUROLOGY | SCIE | 42/280 | Q1 | T1 | D2 |
| NEUROSCIENCES | SCIE | 70/310 | Q1 | T1 | D3 |
Año: 2023
Journal Citation Indicator (JCI): 1,300
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| CLINICAL NEUROLOGY | 41/281 | Q1 | T1 | D2 | 85,59 |
| NEUROSCIENCES | 53/310 | Q1 | T1 | D2 | 83,07 |
Año:
2023
CiteScore:
9,700
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Neurology | 24/192 | Q1 | T1 | D2 |
| Neurology (clinical) | 46/400 | Q1 | T1 | D2 |
SJR año:
2023
Factor de Impacto:
1,560
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Neurology | 25/185 | Q1 | T1 | D2 |
| Neurology (clinical) | 54/398 | Q1 | T1 | D2 |
| Agencia | Código de Proyecto |
|---|---|
| AbbVie | - |
| Alexion Pharma | - |
| Alnylam | - |
| AOP Orphan | - |
| Apopharma Inc. | - |
| Bial | - |
| Biogen | - |
| BMBF | - |
| BMWi | - |
| Boston Scientific | - |
| Christa und Peter Thomsen Foundation | - |
| Consejeria de Economia, Innovacion, Ciencia y Empleo de la Junta de Andalucia | - |
| Consejeria de Salud y Bienestar Social de la Junta de Andalucia | - |
| Coppenrath Foundation | - |
| Cure Parkinson's Trust | - |
| Dapm Foundation | - |
| Defeat MSA | - |
| Desitin | - |
| Edmond J. Safra Foundation | - |
| Else-Kroner-Fresenius Foundation,= | - |
| EU | - |
| Ever Pharma | - |
| Fundacao MSD | - |
| FWF Austrian Science Fund | - |
| GEHealthcare | - |
| Gossweiler Foundation | - |
| Hoffmann La Roche AG | - |
| Icon Ltd + Biohaven Inc. | - |
| Innovate UK | - |
| Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional | - |
| Jan von Appen Foundation | - |
| Janet Owens Research Fellowship | - |
| Janssen Pharmaceutica N.V. | - |
| John Black Charitable Foundation | - |
| Lundbeck | - |
| Medtronic | - |
| Merck Serono | - |
| Michael J. Fox Foundation (MJFF) | - |
| MJFF | - |
| National Institute of Health Research | - |
| Novartis | - |
| Parkinson Fonds Deutschland GmbH | - |
| Pfizer | - |
| Profile Pharma | - |
| Roche AG | - |
| Rosetrees Trust | - |
| Sanofi | - |
| Sivantos GmbH | - |
| Spanish Ministry of Science and Innovation | - |
| Stichting Parkinson Fonds | - |
| UCB | - |
| Van Andel Research Institute | - |
| Zambon | - |
| # | Autor |
|---|---|
| 1 | |
| 2 | Antonini, Angelo |
| 3 | Costa, Joao |
| 4 | Smilowska, Katarzyna |
| 5 | Berg, Daniela |
| 6 | Corvol, Jean-Christophe |
| 7 | Fabbrini, Giovanni |
| 8 | Ferreira, Joaquim |
| 9 | Foltynie, Tom |
| 10 | Mir, Pablo |
| 11 | Schrag, Anette |
| 12 | Seppi, Klaus |
| 13 | Taba, Pille |
| 14 | Ruzicka, Evzen |
| 15 | Selikhova, Marianna |
| 16 | Henschke, Nicholas |
| 17 | Villanueva, Gemma |
| 18 | Moro, Elena |
